Hui Yang, Ruihua Tang, Jing Li, Yaxiong Liu, Ji Li, Linjie Ye, Dongyan Shao, Mingliang Jin, Qingsheng Huang, Junling Shi
Hepatogastroenterology. 2015 Jun;62(140):1002-6.
BACKGROUND/AIMS: To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE).
PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software.
Totally 4 studies, including 527 patients, compared the efficacy and safety of DEB-TACE with cTACE. The DEB-TACE achieved fewer side effects in alopecia (p = 0.0002, RR = 0.05, 95% CI: 0.01-0.24) and myelosuppression (p = 0.009, RR = 0.32, 95% CI: 0.14-0.75). Meanwhile, there was no significant difference in efficacy evaluation including complete response (p = 0.16, RR = 1.36, 95% CI: 0.89-2.08), partial response (p = 0.48, RR = 1.14, 95% CI: 0.80-1.62), stable disease (p = 0.73, RR = 0.93,95% CI: 0.60-1.40), progressive disease (p 0.19, RR = 0.80, 95% CI: 0.56-1.12), objective response (p = 0.26, RR 0.91, 95% CI: 0.48-1.72) and disease control (p = 0.05, RR = 1.18, 95% CI: 1.00-1.39).
DEB-TACE shows similar therapeutic efficacy to cTACE method and fewer adverse events.
背景/目的:评估与传统经动脉化疗栓塞术(cTACE)相比,载药微球经动脉化疗栓塞术(DEB-TACE)的疗效和安全性。
检索PubMed、EMBASE、MEDLINE和Cochrane对照试验注册库,以识别评估DEB-TACE与cTACE疗效和副作用的随机对照试验。采用Revman 5.0软件计算95%置信区间(CI)的相对危险度(RR)。
共有4项研究(包括527例患者)比较了DEB-TACE与cTACE的疗效和安全性。DEB-TACE在脱发(p = 0.0002,RR = 0.05,95%CI:0.01-0.24)和骨髓抑制(p = 0.009,RR = 0.32,95%CI:0.14-0.75)方面副作用更少。同时,在包括完全缓解(p = 0.16,RR = 1.36,95%CI:~0.89-2.08)、部分缓解(p = 0.48,RR = 1.14,95%CI:0.80-1.62)、疾病稳定(p = 0.73,RR = 0.93,95%CI:0.60-1.40)、疾病进展(p = 0.19,RR = 0.80,95%CI:0.56-1.12)、客观缓解(p = 0.26,RR = 0.91,95%CI:0.48-1.72)和疾病控制(p = 0.05,RR = 1.18,95%CI:1.00-1.39)的疗效评估方面,两者无显著差异。
DEB-TACE与cTACE方法显示出相似的治疗效果,且不良事件更少。